Establishment of a Lactylation-Related Gene Signature for Hepatocellular Carcinoma Applying Bulk and Single-Cell RNA Sequencing Analysis

被引:0
作者
Yu, Lianghe [1 ]
Shi, Yan [1 ]
Zhi, Zhenyu [1 ]
Li, Shuang [2 ]
Yu, Wenlong [1 ]
Zhang, Yongjie [1 ]
机构
[1] Naval Mil Med Univ, Affiliated Hosp 3, Hepatobiliary Surg, Shanghai, Peoples R China
[2] Hangzhou Mugu Technol Co Ltd, Bioinformat R&D Dept, Hangzhou, Peoples R China
关键词
bulk RNA-seq; gene signature; hepatocellular carcinoma; immune infiltration; immunotherapy; lactylation; scRNA-seq; IMMUNE INFILTRATION;
D O I
10.1155/ijog/3547543
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Lactylation is closely involved in cancer progression, but its role in hepatocellular carcinoma (HCC) is unclear. The present work set out to develop a lactylation-related gene (LRG) signature for HCC.Methods: The lactylation score of tumor and normal groups was calculated using the gene set variation analysis (GSVA) package. The single-cell RNA sequencing (scRNA-seq) analysis of HCC was performed in the "Seurat" package. Prognostic LRGs were selected by performing univariate and least absolute shrinkage and selection operator (LASSO) Cox regression analyses to develop and validate a Riskscore model. Functional enrichment analysis was conducted by gene set enrichment analysis (GSEA) using the "clusterProfiler" package. Genomic characteristics between different risk groups were compared, and tumor mutational burden (TMB) was calculated by the "Maftools" package. Immune cell infiltration was assessed by algorithms of cell-type identification by estimating relative subsets of RNA transcript (CIBERSORT), microenvironment cell populations-counter (MCP-counter), estimating the proportions of immune and cancer cells (EPIC), tumor immune estimation resource (TIMER), and single-sample gene set enrichment analysis (ssGSEA). Immunotherapy response was predicted by the tumor immune dysfunction and exclusion (TIDE) algorithm. Drug sensitivity was analyzed using the "pRRophetic" package. A nomogram was established using the "rms" package. The expressions of the prognostic LRGs in HCC cells were verified by in vitro test, and cell counting kit-8 (CCK-8), wound healing, and transwell assays were carried out to measure the viability, migration, and invasion of HCC cells.Results: The lactylation score, which was higher in the tumor group than in the normal group, has been confirmed as an independent factor for the prognostic evaluation in HCC. Six prognostic LRGs, including two protective genes (FTCD and APCS) and four risk genes (LGALS3, C1orf43, TALDO1, and CCT5), were identified to develop a Riskscore model with a strong prognostic prediction performance in HCC. The scRNA-seq analysis revealed that LGALS3 was largely expressed in myeloid cells, while APCS, FTCD, TALDO1, CCT5, and C1orf43 were mainly expressed in hepatocytes. The high-risk group was primarily enriched in the pathways involved in tumor occurrence and development, with higher T cell infiltration. Moreover, the high-risk group was found to be less responsive to immunotherapy but was more sensitive to chemotherapeutic drugs. By integrating Riskscore and clinical features, a nomogram with a high predictive accuracy was developed. Additionally, C1orf43, CCT5, TALDO1, and LGALS3 were highly expressed in HCC cells. Silencing CCT5 inhibited the viability, migration, and invasion of HCC cells.Conclusion: The present work developed a novel LRG gene signature that could be considered a promising therapeutic target and biomarker for HCC.
引用
收藏
页数:31
相关论文
共 91 条
[1]  
Chen Y.-C., Chen H.-H., Chen P.-M., Catalase expression is an independent prognostic marker in liver hepatocellular carcinoma, Oncologie, 26, pp. 79-90, (2024)
[2]  
Zhang Y., Feng B., Liang Y., Tang Q., Zhang S., Zhang Z., Xu L., Yin J., Prognostic significance of LRPPRC and its association with immune infiltration in liver hepatocellular carcinoma, American Journal of Clinical and Experimental Immunology, 13, pp. 105-116, (2024)
[3]  
Cui Z., Liu C., Li H., Wang J., Li G., Analysis and validation of tyrosine metabolism-related prognostic features for liver hepatocellular carcinoma therapy, Current Medicinal Chemistry, 32, pp. 160-187, (2025)
[4]  
Sensi B., Angelico R., Toti L., Conte L., Coppola A., Tisone G., Manzia T.M., Mechanism, potential, and concerns of immunotherapy for hepatocellular carcinoma and liver transplantation, Current Molecular Pharmacology, 17, (2024)
[5]  
Li D., Fan X., Zuo L., Wu X., Wu Y., Zhang Y., Zou F., Sun Z., Zhang W., Prognostic analysis of RAS-related lncRNAs in liver hepatocellular carcinoma, Annals of Translational Medicine, 10, (2022)
[6]  
Abdel-Hamid N.M., Al-Quzweny R.M., Prevalence of hepatocellular carcinoma in men and the contribution of androgen and its receptor in pathogenesis and therapy, Current Molecular Pharmacology, 16, pp. 559-563, (2023)
[7]  
Han X., Long W., Liu Y., Xu J., Prognostic value and immunological role of BAIAP2L2 in liver hepatocellular carcinoma: a pan-cancer analysis, Frontiers in Surgery, 9, (2022)
[8]  
Li F., Wang B., Li H., Kong L., Zhu B., G6PD and machine learning algorithms as prognostic and diagnostic indicators of liver hepatocellular carcinoma, BMC Cancer, 24, (2024)
[9]  
Tang J., Zhu C., Chen Y.U.N., Wu Y., He M., Zhou Y.I., Xie M., Identification prognostic features related to sphingolipid metabolism and experimental validation of TRIM47 in hepatocellular carcinoma, Biocell, 48, pp. 639-651, (2024)
[10]  
Zeng W., Ling F., Dang K., Chi Q., SPP1 and the risk score model to improve the survival prediction of patients with hepatocellular carcinoma based on multiple algorithms and back propagation neural networks, Biocell, 47, pp. 581-592, (2023)